stockrow
Saturday 7 November 2026
Export SGMT’s income statement to Excel — free account
Sagimet Biosciences Inc.
SGMT Healthcare Biotechnology
Sagimet Biosciences Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.0 million.
- EPS
- +18.8%
- Free cash flow
- −22.0%
Quarter to June 2026, against a year earlier
9.82
0.70
+7.68%
Follow SGMT
Alert me
Sagimet Biosciences Inc. (SGMT) P/E ratio
Sagimet Biosciences Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2023 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DBVT DBV Technologies S.A. compare | n/m |
| SLDB Solid Biosciences Inc. compare | n/m |
| ACHV Achieve Life Sciences, Inc. compare | n/m |
| FDMT 4D Molecular Therapeutics, Inc. compare | n/m |
| SGMT Sagimet Biosciences Inc. | n/m |
| CADL Candel Therapeutics, Inc. compare | n/m |
| AURA Aura Biosciences, Inc. compare | n/m |
| WVE WAVE Life Sciences Ltd. compare | n/m |
| ZVRA Zevra Therapeutics, Inc. compare | 9.0× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)